TOP1MT
ENSG00000184428
Target class
Enzyme
Chromosome
8
- Chemical probe available
- No
- Target name
- TOP1MT
- Gene name
- DNA topoisomerase I mitochondrial
- Gene symbol
- TOP1MT
- Protein name
- DNA topoisomerase I, mitochondrial (TOP1mt) (EC 5.6.2.1)
- Gene biotype
- Protein coding
- Gene family
- Topoisomerases|Mitochondrial nucleoid associated proteins
- Target class
- Enzyme
- Target type
- Human gene
- Tissues expressed in
- 51
- Protein localisation evidence grade
- Supported
- Highest tissue expression
- 20.1
- Tissue specificity (Gini)
- 0.368
- Tissue specificity (tau)
- 0.681
- KEGG gene identifiers
- hsa:116447
- Protein interaction confidence
- 0.8321
- Protein interaction partners
- 10
- End position
- 143359979
- Start position
- 143304384
- Chromosome
- 8
- Strand
- Reverse
- Mitochondrion .
- Mitochondria
Publication evidence
- PubMed 11526219
- Tissue specificity (tau)
- 0.680719
- Expression inequality (Gini)
- 0.367638
Expression in transcripts per million
- Testis
- 20.1
- Ovary
- 18.68
- Cervix - Endocervix
- 16.81
- Cervix - Ectocervix
- 15.88
- Thyroid
- 12.84
Expression in transcripts per million
- Testis20.1
- Ovary18.68
- Cervix - Endocervix16.81
- Cervix - Ectocervix15.88
- Thyroid12.84
- Vagina12.29
- Skin - Not Sun Exposed (Suprapubic)12.07
- Bladder11.76
- Uterus11.34
- Skin - Sun Exposed (Lower leg)10.68
- Cells - Cultured fibroblasts9.26
- Fallopian Tube8.78
- Esophagus - Mucosa8.68
- Prostate8.38
- Breast - Mammary Tissue8.15
- Adrenal Gland8.13
- Cells - EBV-transformed lymphocytes7.86
- Adipose - Subcutaneous7.8
- Adipose - Visceral (Omentum)7.4
- Artery - Aorta7.28
- Colon - Sigmoid7.21
- Lung7.12
- Spleen7.11
- Liver6.97
- Nerve - Tibial6.96
And 29 more, listed on the interactive page.
- GO:0005739
- GO:0042645
Related records
Trials (264)
- 9-ING-41 in Pediatric Patients With Refractory Malignancies.
- A Bioequivalence Study of Two Oral Formulations of Topotecan in Patients With Advanced Solid Tumors
- A Multi-Arm, Platform Trial For Relapsed Neuroblastoma
- a Multicenter Clinical Trial for the Treatment of Children and Adolescents With Soft Tissue Sarcoma Stage 4
- A Pharmacokinetic Study of Oral Cyclophosphamide and Topotecan in Children With Recurrent Solid Tumors
- A Phase 1b Study of Sevacizumab in Combination With Chemotherapy in Chinese Patients With Platinum-Resistant Recurrent Ovarian Cancer.
- A Phase 2 Study Comparing TAS-102 Versus Topotecan or Amrubicin to Treat Small Cell Lung Cancer Following Platinum-Based Chemotherapy
- A Phase I Study of CCI-779 (Temsirolimus) in Combination With Topotecan in Patients With Gynecologic Malignancies
- A Phase I Study of Oral Topotecan as a Radiosensitizing Agent in Patients With Rectal Carcinoma
- A Phase I Topotecan Study in Subjects With Cancer and Impaired Renal Function
- A Phase I/II Study of Induction Chemotherapy With Daunorubicin, Cytarabine, Topotecan and Etoposide
- A Phase II Study of Paclitaxel and Topotecan With Filgrastim-SD/01 Support For Relapsed and Refractory Aggressive Non-Hodgkin's Lymphoma
- A Phase II Study of Topotecan in Children With Recurrent Wilms Tumor
- A Phase III Study of BD0801 Combined With Chemotherapy in Recurrent, Platinum-resistant Epithelial Ovarian Cancer
- A Pilot Trial of Oral Topotecan for the Treatment of Refractory Advanced Solid Neoplasms Expressing HIF-1a
- A Prospective International Multicenter Clinical Trial for Eyes With Relapsed Retinoblastoma
- A Randomized Study to Compare the Efficacy and Safety of Belotecan and Topotecan as Monotherapy for Sensitive-Relapsed Small Cell Lung Cancer
- A Study Comparing BL-B01D1 With Topotecan in Patients With Recurrent Small Cell Lung Cancer(PANKU-Lung03)
- A Study Comparing BL-M07D1 With Physician's Choice of Chemotherapy in Patients With HER2-Expressing Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer
- A Study Evaluating BSI-201 in Combination With Chemotherapeutic Regimens in Subjects With Advanced Solid Tumors